PD-L1 Promotes Tumor Progression, Chemotherapy Resistance, and Poor Clinical Outcomes in Non-Small C

来源 :第十八届全国临床肿瘤学大会暨2015年CSCO学术年会 | 被引量 : 0次 | 上传用户:swatsee
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
  Objective: Although neoadjuvant chemotherapy (NAC) for advanced lung cancer can improve operability and local disease control, the duration of benefit is limited before resistance develops.
其他文献
Objective: Several phase Ⅲ studies demonstrated that, compared with traditional chemotherapy, epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), as first-linetreatments, contribu
Objective: To assess differences in overall survival among patients with NSCLC using TKIs in first or second line treatment and different TKIs.Method: Collecting patients data in CRF and use SPSS soft
Objective: To investigate the efficacy and safety of the treatment of nitroglycerin combined with docetaxel/carboplatin chemotherapy for the elderly patients with advanced non-small cell lung cancer (
目的:通过吉非替尼(gefitinib)和厄洛替尼(erlotinib)双重耐药非小细胞肺癌(NSCLC)细胞HCC827/ER研究消癌平注射液(XAP)改善gefitinib和erlotinib耐药的作用及机理。方法:通过erlotinib 长期诱导形成耐药细胞株HCC827/ER,MTT检测细胞增殖,Taqman探针实时荧光定量PCR检测Met基因拷贝数,Western blot法检测细胞蛋白
Objective: Proteinkinase CK2 (also known ascasein kinase) is a highlyconserved seine/threonine protein kinase, which is ubiquitously expressed inmammalian cells.CK2 has been implicated in multiple phy
Objective: Stem-like cells in solid tumors are purported to contribute to cancer development and poor treatment outcome.The abilities to self-renew, differentiate, and resist anticancer therapies are
Objective: For patients with locally advanced non-small-cell lung cancer (LA-NSCLC), the role of consolidation chemotherapy (CCT) following concurrent chemoradiotherapy (CRT) is partially defined.
Objective: Tumor initiating cells (TICs) are a small subpopulation within cancer that is thought to be resistant to conventional therapiesand capable of reinitiating tumors.
Objective: Central nervous system (CNS) progression is frequently detected in patients with favorable initial responses to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors (EGFR-TKIs), but
Objective: Lung cancer is the leading cause of cancer related death in the world.The last decade has witnessed the rapid development of epidermal growth factor receptor (EGFR) directed targeted therap